Marrow Therapeutics raised $173 million to advance a “Trojan Horse” delivery approach for blood-disorder drugs, targeting sickle cell disease and beta thalassemia as lead indications. The company positioned the platform as a path to broaden access by improving manufacturing and dosing logistics compared with conventional gene therapies. The funding underscores investor focus on delivery and manufacturing bottlenecks in inherited blood disorders, where ex vivo workflows and vector supply constraints remain major scale-up challenges. Marrow’s financing also highlights continued appetite for platform-driven cell and gene medicine that can potentially reduce patient- and system-level friction. While specific clinical milestones weren’t detailed in the report, the size and timing of the round suggest Marrow is moving toward tangible development execution for its internally led candidates. The company’s public timeline will be closely watched as it translates delivery design into clinical endpoints. For investors and operators, the key takeaway is that capital is flowing to approaches that address both biological activity and real-world deliverability—an increasingly decisive factor in gene and cell therapy commercialization.